Axcynsis Therapeutics, a Singapore-based biotech startup that develops antibody-drug conjugates (ADCs) for cancer therapy and was formerly known as Tetris Therapeutics, received $10 million last week as part of a $15 million seed round announced in May.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
